Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neuritis 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 93Radiotherapy 66Bevacizumab 35Radiation 22Carmustine 21Erlotinib Hydrochloride 17Chemotherapy, Adjuvant 17Irinotecan 16Magnetic Resonance Spectroscopy 13Radiotherapy, Conformal 11O(6)-benzylguanine 11Surgical Procedures, Operative 10Radiotherapy, Intensity-Modulated 10sargramostim 9Sirolimus 9Imatinib Mesylate 9Carboplatin 9temsirolimus 8motexafin gadolinium 7Thalidomide 7Gene Expression Profiling 7aldesleukin 6Sorafenib 6Radiosurgery 6Immunohistochemistry 6Hydroxyurea 6Gefitinib 6Filgrastim 6Everolimus 6Etoposide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × Diffusion Tensor Imaging × Clear all
NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
46 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡